Health Trials

A Study of NX-1607 in Adults With Advanced Malignancies

ConditionsOvarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) CancerHead and Neck Squamous Cell CarcinomaMetastatic or Unresectable MelanomaNon-small Cell Lung Cancer (NSCLC)Metastatic Castration-resistant Prostate Cancer (mCRPC)Malignant Pleural Mesothelioma (MPM)Triple Negative Breast Cancer (TNBC)Metastatic Urothelial CarcinomaCervical CancerDiffuse Large B Cell Lymphoma (DLBCL)Richter TransformationMicrosatellite Stable Colorectal Carcinoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorNurix Therapeutics, Inc.

About this trial

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Eligibility criteria

Qualifiers

Age ≥ 18 years.

Measurable disease per disease-specific response criteria.

Patients must have disease that is metastatic or unresectable and have received standard treatment options, are not candidates for standard treatment options, or will otherwise be prevented from receiving any standard treatment options.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Disqualifiers

Active untreated brain metastases.

Uncontrolled intercurrent illness including, but not limited to, poorly controlled hypertension or diabetes, or ongoing active infection requiring systemic therapy.

Patients with primary refractory EOC defined as patients who do not respond to their first platinum-containing regimen or who relapse less than 6 months after completion of that first platinum-containing regimen

Psychiatric illness that would limit compliance with study requirements.

Trial design

Treatments tested in this trial

  • NX-1607
  • Paclitaxel

Treatment groups

345 Participants
are divided into 12 treatment groups

12

Treatment groups

See each treatment group below.

Sponsors and collaborators

Nurix Therapeutics, Inc.

Lead sponsor

Source ClinicalTrials.gov